The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk: London, UK Wednesday, July 16, 2025, 14:00 Hrs [IST] GSK ...

London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend ...

GSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

Residents in public residential aged care services aged 60 and over can now claim a free vaccine for Respiratory Syncytial ...

The disease was found following tests on a severely emaciated doe that was euthanized and tested in early June, Andrea Korman ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and Pfizer's PFE.N Abrysvo.

Frailty strongly predicts worse RSV outcomes in older adults, highlighting the need for targeted care as aging populations face rising infection risks.

Recent studies have shown convincingly that vaccines against shingles (Herpes zoster) reduce the risk of dementia.

This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segment. Tuesday, 02 January 2024 12:17 GMT.